Voda Feed Innovations
Introducing a Novel, Multidimensional Feed Additive for Ruminants
Next Generation Chemistry
This patent pending, next generation feed additive is a novel chemistry designed to deliver multidimensional performance in a single, low dose granular powder.
Unlike antibiotics, does not succumb to bacterial resistance due to a unique, binary mode of efficacy to target bacteria.
Selective to target organisms, promotes preferred ruminant microbiome.
Reduces to natural byproducts, supporting clean label designation.
Drop in product, compatible with existing micro-dosing systems.
Does not impart taste or order for palatability.
ONE DOSE - MULTIPLE OUTCOMES
The only feed additive that demonstrates multiple aspects with one dose.
Tylosin & Antibiotic Replacement
- Target bacteria responsible for Liver Abscess
- Replace with “clean label” product
- Eliminate or reduce antibiotic requirement
GHG Emissions
- Target Archaea bacteria responsible for Methane production
- Redirect this pathway to feed efficiency
Food & Animal Safety
- Increase safety by reducing pathogens such as Salmonella and E.coli
- Natural byproducts will not harm animal or environment
- Perform as probiotic
Organic & Natural Beef
- Clean Label approval will permit this market to utilize Camp 66
- Provide a tool not currently available to this segment to improve productivity
KEY CUSTOMER SEGMENTS
Dairy Producers
Diary producers seek clean label, non-antibiotic compliance and sustainability to meet market demands effectively.
Beef Producers
Beef producers seek improved cattle growth, compliance and sustainability to meet market demands effectively.
Other Ruminants
Sheep/Goat Producers.
All ruminates are a target market.
CSU - ANIMAL SCIENCE RESEARCH
VFI is partnered with Colorado State University (CSU) Animal Science academic research group led by Dr. Jennifer Martin, a recognized global leader in this field. Initial laboratory analysis began in early 2024 to validate chemistry for the multidimensional application to ruminants and continues.
As of 2026, the program has advanced to in vivo (live animal) trials, marking a significant milestone in validation of both the chemistry and positive biological impact on the animal.
VFI FOUNDER & CEO
Allen Ziegler brings 35 years of experience developing and commercializing novel antimicrobials for the food and agriculture industry across both Fortune 500 and high growth startup companies. He holds several patents and patents pending in antimicrobial chemistry, with a focus on antibiotic-replacement products and technologies.
He has served in C-suite roles and as a startup Founder/President, with a proven track record end-to-end life cycle experience including product development, startup launch, commercial scale-up, and company sale.
Demonstrates multiple aspects with one dose.
MULTIDIMENSIONAL MODE OF ACTION
Can Replace the Use of Tylosin
Positively ImpactsRuminant Microbiome
Increases FoodSafety for Both theAnimal and Consumer
First “Clean Label” Antimicrobial
